GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BOLT · Jun 30, 2025

Bolt Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001641281-25-000007General Corporate
Operating cash generation92thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-531.98% · OPTIONAL · VALID

Revenue growth88thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

41.49% · CORE · VALID

Operating margin92thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-510.53% · CORE · VALID

R&D intensity8thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

415.63% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

34.65% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible
Period transition

What moved in the state?

Cash Generation Increased
Previous
-1093.70%
Current
-531.98%
Delta
561.71%
Growth Increased
Previous
-76.83%
Current
41.49%
Delta
118.32%
Profitability Increased
Previous
-991.41%
Current
-510.53%
Delta
480.88%
R And D Intensity Decreased
Previous
778.40%
Current
415.63%
Delta
-362.76%
Sbc Intensity Decreased
Previous
58.02%
Current
34.65%
Delta
-23.37%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.